Search

Displaying results 5491 - 5500 of 8697 in total
  1. Drug

    Apitegromab

    go.drugbank.com/drugs/DB16096
    ApprovedInvestigational

    Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).

  2. Drug

    XPro1595

    go.drugbank.com/drugs/DB16454
    Investigational

    XPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    Salicylamide

    go.drugbank.com/drugs/DB08797
    Approved

    Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties.

  4. Drug

    ODN M362

    go.drugbank.com/drugs/DB16485
    Experimental

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Verubecestat

    go.drugbank.com/drugs/DB12285
    Investigational

    In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. … Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment.

  6. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma. … Reglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug.

  7. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752] … AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.

  8. Drug

    Dihydroergocristine

    go.drugbank.com/drugs/DB13345
    Approved

    [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Forasartan

    go.drugbank.com/drugs/DB01342
    Experimental

    Forasartan competes with angiotensin II for binding at the AT1 receptor subtype.

    Categories: Angiotensin Receptor Antagonists, Angiotensin II receptor antagonists
  10. Drug

    Carotuximab

    go.drugbank.com/drugs/DB06322
    Investigational